Education
About Us
Working with TipRanks
Follow Us
Lantheus (LNTH)
NASDAQ:LNTH
LNTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$47.25 - $118.21
Previous CloseN/A
Volume177.90K
Average Volume (3M)1.35M
Market Cap
$3.58B
Enterprise Value$5.68B
Total Cash (Recent Filing)$695.57M
Total Debt (Recent Filing)$615.49M
Price to Earnings (P/E)14.0
Beta0.43
Next Earnings
Oct 30, 2025EPS Estimate
1.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding67,994,150
10 Day Avg. Volume1,607,020
30 Day Avg. Volume1,353,539
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue3.73
Enterprise Value/Gross Profit5.85
Enterprise Value/Ebitda12.41
Forecast
1Y Price Target
$83.71Price Target Upside58.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Long-term Growth PotentialThere is underappreciated value in LNTH's long-term pipeline, with potential for revenue and EPS growth expected in the future.
Stock BuybackThe Board of Directors authorized the repurchase of up to $400M of LNTH's common stock, which can be seen as a vote of confidence in the company's future value.
Strategic AcquisitionsThe acquisition of Life Molecular Imaging added the FDA-approved NEURACEQ to LNTH's portfolio, expanding its diagnostic and therapeutic capabilities.
Bears Say
Competitive PressuresSustained competitive pressure is creating headwinds for the company's lead asset, PYLARIFY, which resulted in a notable stock price drop.
Financial Guidance ReductionThe company lowered its guidance for the fiscal year, indicating significant cuts in both revenue and EPS projections.
Market ChallengesManagement highlighted intensified competitive pressures in the market, particularly affecting Pylarify revenues.
Lantheus News
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $47.25 and its highest was $118.21 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $3.58B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Oct 30, 2025 which is in 22 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Aug 06, 2025. The company reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.675 by -$0.105.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.28.
How many shares outstanding does Lantheus have?
Lantheus has 67,994,150 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.57 in its last earnings report, missing expectations of $1.675. Following the earnings report the stock price went down -28.583%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in LNTH
Lantheus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.71 (58.84% Upside)
$83.71 (58.84% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 217.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $382.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.10%
12-Months-Change
Fundamentals
Return on Equity
24.71%
Trailing 12-Months
Asset Growth
9.09%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. is a global leader in the development, manufacturing, and commercialization of innovative diagnostic imaging agents and therapies, primarily focused on oncology, cardiology, and neurology. The company specializes in radiopharmaceuticals and molecular imaging, offering products that aid in the detection and treatment of various diseases, including cancer. Its core products include Positron Emission Tomography (PET) imaging agents and other medical imaging solutions that enhance diagnostic accuracy and patient care.
LNTH Company Deck
LNTH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strategic moves to enhance the company's portfolio and diversify revenue streams, such as the FDA acceptance of a new PYLARIFY formulation and key acquisitions. However, it also addressed significant challenges, including a lowered financial outlook and competitive pressures affecting PYLARIFY sales. Despite strategic efforts, the lowlights weigh heavily, indicating ongoing market challenges.View all LNTH earnings summariesLNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
LNTH Stock 12 Month Forecast
Average Price Target
$83.71
▲(58.84% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
2.07% Insiders
40.31% Mutual Funds
4.25% Other Institutional Investors
26.13% Public Companies and Individual Investors